VLX-1005
- Generic Name
- VLX-1005
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19N3O4S2
- CAS Number
- 1532593-30-8
- Unique Ingredient Identifier
- JKU4XCC48Y
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Veralox Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT05785819
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Veralox Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT05325346
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
Phase I Study of VLX-1005 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Veralox Therapeutics
- Target Recruit Count
- 96
- Registration Number
- NCT04783545
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath